Cargando…

Advances of Targeted Therapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a significant global health problem. The clinical applicability of traditional surgery and other locoregional therapies is limited, and these therapeutic strategies are far from satisfactory in improving the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Mengke, Yi, Ming, Li, Ning, Wu, Kongju, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350567/ https://www.ncbi.nlm.nih.gov/pubmed/34381735 http://dx.doi.org/10.3389/fonc.2021.719896

Ejemplares similares

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Recent advances in oncolytic virus therapy for hepatocellular carcinoma
por: Zhu, Licheng, et al.
Publicado: (2023)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials
por: Zhang, Yun-Long, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma
por: Shen, Jie, et al.
Publicado: (2021)

The advanced development of molecular targeted therapy for hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2022)

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
por: Lyu, Ning, et al.
Publicado: (2020)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Ping, et al.
Publicado: (2023)

Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway
por: Mranda, Geofrey Mahiki, et al.
Publicado: (2022)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection
por: Xiao, Han, et al.
Publicado: (2021)

Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma
por: Yang, Ye, et al.
Publicado: (2021)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Progress of MRI Radiomics in Hepatocellular Carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2021)

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
por: Xu, Junnv, et al.
Publicado: (2021)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Application and progress of palliative therapy in advanced gastric carcinomas
por: Luo, Xiao-fan, et al.
Publicado: (2023)

Identification of DNA repair gene signature and potential molecular subtypes in hepatocellular carcinoma
por: Bai, Yi, et al.
Publicado: (2023)

CT-pathologic correlation in primary hepatocellular carcinoma: an implication for target delineation
por: Chen, Hai-yan, et al.
Publicado: (2013)

Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma
por: Fan, Zhe, et al.
Publicado: (2021)

Proton therapy in the treatment of hepatocellular carcinoma
por: Dionisi, Francesco, et al.
Publicado: (2022)

Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application
por: Liu, Sha, et al.
Publicado: (2022)

Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement
por: Trotovsek, Blaz, et al.
Publicado: (2022)

Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
por: Wu, Jun-Yi, et al.
Publicado: (2021)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response
por: He, Penghui, et al.
Publicado: (2022)

Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
por: Zheng, Xiufeng, et al.
Publicado: (2022)

Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy
por: Xue, Jian, et al.
Publicado: (2021)

Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma
por: Xia, Haoming, et al.
Publicado: (2022)

Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma
por: Liu, Peng, et al.
Publicado: (2020)

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival
por: Xu, Hanxiao, et al.
Publicado: (2019)

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation
por: Qin, Shuang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_31ekom20c5lso2v80ogts6iu8b